What is the recommended dose and duration of oral terbinafine for treating tinea capitis in children, including weight‑based dosing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Terbinafine Dosing for Tinea Capitis

For tinea capitis caused by Trichophyton species, use weight-based terbinafine dosing for 2-4 weeks: 62.5 mg daily for children <20 kg, 125 mg daily for 20-40 kg, and 250 mg daily for >40 kg. 1

Weight-Based Dosing Algorithm

The British Association of Dermatologists provides clear weight-based dosing 1:

  • <20 kg: 62.5 mg daily for 2-4 weeks
  • 20-40 kg: 125 mg daily for 2-4 weeks
  • >40 kg: 250 mg daily for 2-4 weeks

Critical Decision Point: Organism Matters

The causative organism fundamentally determines whether terbinafine is appropriate:

  • Trichophyton species (T. tonsurans, T. violaceum, T. soudanense): Terbinafine is highly effective and superior to griseofulvin 1, 2, 3
  • Microsporum species (M. canis, M. audouinii): Terbinafine performs poorly—griseofulvin is significantly more effective 1, 3

This species-specific efficacy exists because terbinafine is not excreted in sweat or sebum of prepubertal children and cannot be incorporated into the hair shaft, preventing it from reaching scalp surface arthroconidia in Microsporum infections 1.

Optimal Treatment Duration

Two weeks is the optimal duration for Trichophyton infections when balancing efficacy, cost, and compliance. A randomized trial of 159 patients demonstrated that 2-week treatment achieved 69% effective cure versus 65% for 4 weeks and only 56% for 1 week 4. The 2-week regimen was clinically superior to 1 week, while 4 weeks provided no additional benefit over 2 weeks.

However, the British guidelines recommend 2-4 weeks, acknowledging that some cases may require the longer duration 1. If clinical improvement occurs but mycology remains positive, continue therapy for an additional 2-4 weeks 1.

Common Pitfalls to Avoid

  1. Don't use terbinafine empirically without considering local epidemiology. In regions where Microsporum predominates, griseofulvin should be first-line 1.

  2. Don't stop at clinical improvement alone. The endpoint is mycological cure, not just clinical resolution. Repeat mycology sampling until clearance is achieved 1.

  3. Don't assume higher doses or longer duration improve efficacy. At higher doses, terbinafine is more effective, but prolonging treatment beyond 2-4 weeks does not improve outcomes for Trichophyton 1, 4.

Treatment Failure Management

If treatment fails, first consider 1:

  • Non-compliance
  • Suboptimal drug absorption
  • Organism insensitivity (likely Microsporum)
  • Reinfection

For persistent Trichophyton infections with clinical improvement but positive cultures: Continue terbinafine for another 2-4 weeks.

For no clinical improvement: Switch to second-line therapy with itraconazole (5 mg/kg/day for 2-4 weeks) or griseofulvin for Microsporum species 1.

Safety Profile

Terbinafine is well-tolerated in children, with gastrointestinal disturbances and rashes occurring in <8% of patients, and only 0.8% requiring discontinuation 1. The FDA label notes that terbinafine is not currently licensed for tinea capitis in children, though it has extensive off-label use supported by guideline recommendations 5.

Adjunctive Measures

While oral therapy is essential (topical therapy alone is inadequate 1), consider antifungal shampoos (ketoconazole 2%, selenium sulfide 1%) to reduce spore transmission 1. Children on appropriate therapy should attend school or nursery 1.

For T. tonsurans cases, screen and treat all family members and close contacts, as asymptomatic carriers with high spore loads warrant systemic treatment 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.